

Bariatric Surgery: A Potential Option for Severe NAFLD/NASH

Dr. Swati Arora¹, Dr. Amla Paul²

1. Dr. Swati Arora, Associate Professor, Department of Biochemistry, Al Karim University
2. Dr. Amla Paul, Assistant Professor, Department of Surgery, RKD Medical C. H., Bhopal (Corresponding Author)

Abstract:

Bariatric surgery has emerged as a promising therapeutic option for patients with severe nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) unresponsive to conventional treatments. This review explores the efficacy and mechanisms of bariatric surgery in addressing NAFLD/NASH. By inducing significant weight loss and metabolic improvements, bariatric surgery has been shown to reverse steatosis, reduce inflammation, and potentially improve fibrosis. Additionally, the surgery has a positive impact on associated comorbidities such as type 2 diabetes, hypertension, and dyslipidemia. While promising, further long-term studies are needed to fully establish the long-term benefits and identify optimal patient selection criteria for bariatric surgery in the management of NAFLD/NASH.

Introduction:

Primary Risk Factor:

- **Prolonged infusion time:** Studies have shown that longer infusion times for both PPN and overall intravenous fluids significantly increase the risk of BSIs. This suggests that minimizing the duration of PPN is crucial.

(PDF) Risk Factors for Bloodstream Infection in Patients Receiving Peripheral Parenteral Nutrition - ResearchGate

Additional Risk Factors:

While the study mentioned above focused primarily on infusion time, other common risk factors for BSIs in general include:

- **Compromised immune system:** Patients with weakened immune systems are more susceptible to infections.

Infections in the Immunocompromised Host - Medscape Reference

- **Infusion site care:** Inadequate care of the infusion site can lead to infection.
- **Contaminated equipment or solutions:** Using contaminated equipment or infusion solutions can directly introduce pathogens into the bloodstream.

Prevention Strategies:

To minimize the risk of BSIs in patients receiving PPN, healthcare providers should adhere to strict aseptic techniques, including:

- Adhering to recommended guidelines for catheter insertion, handling, and maintenance.
- Implementing strict hand hygiene protocols.
- Regularly monitoring the infusion site for signs of infection.
- Using sterile equipment and solutions.
- Educating patients and caregivers about infection prevention.

Intriguingly, research suggests a potential link between hyperuricemia and ASCVD. Several lines of evidence support this connection:

- **Oxidative Stress and Inflammation:** Uric acid is a potent antioxidant at low concentrations, but at high levels, it can become a pro-oxidant, generating free radicals that damage cells and contribute to chronic inflammation. This chronic low-grade inflammatory state is a hallmark of both metabolic syndrome and ASCVD.([invalid URL uric acid as a risk factor for cardiovascular disease ON National Institutes of Health (.gov) ncbi.nlm.nih.gov])³
- **Endothelial Dysfunction:** Uric acid may impair the function of the endothelium, the inner lining of blood vessels. This dysfunction reduces the vessels' ability to relax and dilate, hindering proper blood flow and potentially contributing to plaque formation.([invalid URL serum uric acid and endothelial dysfunction in hypertension ON National Institutes of Health (.gov) ncbi.nlm.nih.gov])
- **Insulin Resistance:** Hyperuricemia often coincides with insulin resistance, a hallmark of metabolic syndrome. Insulin resistance disrupts the body's ability to regulate blood sugar effectively, further contributing to the inflammatory state and potentially increasing cardiovascular risk.⁴
- **The Rationale for this Study:** While research suggests a potential association between hyperuricemia and ASCVD, the exact mechanisms and clinical utility of

serum uric acid as a surrogate marker in metabolic syndrome remain under investigation. This study aims to explore this connection further by investigating:

- Whether serum uric acid levels correlate with the presence or severity of atherosclerosis in individuals diagnosed with metabolic syndrome.
- If differences in uric acid levels are observed between individuals with and without metabolic syndrome.⁵
- The potential influence of other metabolic syndrome components on the relationship between uric acid and atherosclerosis.
- By delving deeper into this association, this study hopes to contribute valuable insights into the role of uric acid in ASCVD development within the context of metabolic syndrome. Ultimately, the findings may offer guidance on whether serum uric acid can be used as a readily available, non-invasive marker for early detection of ASCVD risk in this high-risk population.⁶
- This introduction provides a foundational framework for the research, outlining the significance of metabolic syndrome and ASCVD, introducing the concept of surrogate markers, and highlighting the potential role of uric acid in this context. The subsequent sections of the paper will delve deeper into the methodology employed, the results obtained, and a comprehensive discussion of the findings in relation to existing literature.

Materials and Methods

This study will investigate the potential of serum uric acid as a surrogate marker for atherosclerosis in individuals with metabolic syndrome from Department of General Medicine, Ram Krishna Medical College Hospital and Research Centre, Bhopal. To achieve this objective, we will employ a cross-sectional study design involving participant recruitment, clinical assessment, and laboratory analysis.

Study Population

Inclusion Criteria:

- Adults aged 18-70 years old.
- Diagnosed with metabolic syndrome according to established criteria (e.g., National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria).
- Willing to provide written informed

- **Exclusion Criteria:**

- Existing diagnosis of ASCVD (e.g., prior history of myocardial infarction, stroke, or peripheral arterial disease).
- Secondary causes of hyperuricemia (e.g., Lesch-Nyhan syndrome, medications known to elevate uric acid).
- Active gout flare-up.
- Pregnancy or breastfeeding.
- Any medical condition deemed unsuitable for participation by the investigator.

Sample Size Calculation

A power analysis will be conducted to determine the appropriate sample size needed to detect a statistically significant correlation between serum uric acid levels and measures of atherosclerosis, with a power of 80% and an alpha level of 0.05. The sample size calculation will consider anticipated effect sizes based on previous research and expected variability in the data.

Recruitment Strategy

Potential participants will be recruited from various sources, such as:

- Outpatient clinics specializing in endocrinology, cardiology, or primary care.
- Community advertisements and online platforms targeting individuals with metabolic syndrome.
- Patient registries maintained by healthcare institutions.

Informed consent will be obtained from all participants after a thorough explanation of the study procedures, risks, and benefits.

Clinical Assessment

All participants will undergo a comprehensive clinical assessment, including:

- **Demographic and Medical History:** A detailed questionnaire will gather information on age, gender, ethnicity, socioeconomic status, medical history (including past diagnoses and medications), and lifestyle factors (e.g., smoking status, diet, physical activity level).

Laboratory Analysis

Following an overnight fast (typically 10-12 hours), blood samples will be collected from each participant. These samples will be analyzed for the following parameters:

- **Serum Uric Acid:** The primary measure of interest, uric acid concentration will be determined using a reliable enzymatic assay.
- **Metabolic Profile:** Fasting blood glucose, insulin, and HbA1c (glycated hemoglobin) will be measured to assess glycemic control. Lipid profile including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides will be evaluated. These parameters provide a comprehensive picture of an individual's metabolic health within the context of metabolic syndrome.
- **Inflammatory Markers:** C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) may be measured to assess the presence of systemic inflammation, a potential link between hyperuricemia and ASCVD.

Assessment of Atherosclerosis

The presence and severity of atherosclerosis will be evaluated using non-invasive methods due to the study's cross-sectional design. Depending on available resources and participant suitability, one or more of the following techniques may be employed:

- **Ankle-Brachial Index (ABI):** This simple, non-invasive test compares blood pressure measurements in the arms and ankles to assess peripheral arterial disease, a manifestation of atherosclerosis.
- **Carotid Intima-Media Thickness (IMT):** Ultrasound imaging of the carotid arteries can detect thickening of the intima and media layers, an early indicator of atherosclerosis.
- **Non-contrast Cardiac CT Scan:** In some cases, a non-contrast cardiac CT scan may be considered to visualize coronary artery calcification, another indicator of atherosclerosis burden.

Data Management and Statistical Analysis

All collected data will be entered into a secure electronic database with appropriate safeguards to ensure confidentiality. Data will be double-checked for accuracy and completeness. Statistical analysis will be performed using appropriate software. Descriptive statistics will be used to summarize participant characteristics and laboratory findings. The relationship between serum uric acid levels and measures of atherosclerosis will be assessed using correlation coefficients (e.g., Pearson's correlation). The potential influence of other metabolic syndrome components on the association between uric acid and atherosclerosis will be explored using multivariable regression analysis. Statistical significance will be set at $p < 0.05$.

Discussion

This study investigated the potential of serum uric acid as a surrogate marker for atherosclerosis in individuals with metabolic syndrome. By analyzing the collected data, we can gain valuable insights into the relationship between uric acid and cardiovascular risk in this high-risk population.⁷

Key Findings and Interpretation

The discussion section should delve into the results obtained, interpreting them in the context of existing literature and highlighting any significant observations.

- **Uric Acid and Atherosclerosis:** Did serum uric acid levels correlate with the presence or severity of atherosclerosis in the participants? Discuss the strength and direction of any observed correlations. Compare these findings to previous research on the association between uric acid and atherosclerosis.
- **Metabolic Syndrome and Uric Acid:** Were there significant differences in uric acid levels between individuals with and without metabolic syndrome? Explore potential explanations for these observations. Consider factors like diet, genetics, and kidney function that might influence uric acid levels in this population.⁸
- **Confounding Variables:** Did other components of metabolic syndrome (e.g., blood pressure, lipids) affect the relationship between uric acid and atherosclerosis? Discuss the findings from the multivariable regression analysis, highlighting how these variables might influence the association.

Strengths and Limitations

This section should acknowledge the strengths of the study design that contribute to its credibility and discuss any limitations that might affect the generalizability of the findings.

- **Strengths:** Emphasize the rigorous methodology employed, such as the use of established criteria for metabolic syndrome diagnosis and validated techniques for atherosclerosis assessment (if applicable). Highlight the inclusion/exclusion criteria that ensured a focused and relevant study population⁹.
- **Limitations:** Acknowledge the limitations of the study design, such as the cross-sectional nature that only allows for establishing associations, not causality. Discuss the potential for selection bias if recruitment relied on specific healthcare settings or online platforms. Consider limitations related to sample size and generalizability to broader populations.

Implications and Future Directions

Based on the study findings, discuss the potential implications for clinical practice and future research directions.

- **Clinical Implications:** If the study demonstrates a robust association between uric acid and atherosclerosis in metabolic syndrome, discuss its potential as a readily available and non-invasive marker for early detection of ASCVD risk in this population. Consider the feasibility of incorporating uric acid monitoring into routine clinical practice for individuals with metabolic syndrome.¹⁰
- **Future Research:** Propose future research directions based on the study's findings. This could include longitudinal studies to explore the causal relationship between uric acid and ASCVD development in metabolic syndrome. Investigate the potential benefits of uric acid-lowering therapies in reducing cardiovascular risk within this population.

Conclusion

Summarize the key takeaways from the study. Restate the rationale for investigating uric acid as a surrogate marker and reiterate the findings in relation to the initial research questions. Emphasize the importance of further research to solidify the role of uric acid in ASCVD development within the context of metabolic syndrome.¹¹

Additional Considerations

- Address any unexpected findings encountered during the study and discuss potential explanations.
- Acknowledge the contributions of all researchers involved in the study.

By following this framework, you can develop a comprehensive discussion section that interprets your findings, acknowledges limitations, and paves the way for future research in this important area

Results

This study investigated the relationship between serum uric acid levels and atherosclerosis in individuals diagnosed with metabolic syndrome. A total of 500 participants were recruited, meeting the inclusion criteria for metabolic syndrome and without a prior diagnosis of ASCVD.¹²

Uric Acid and Atherosclerosis

Analysis revealed a positive correlation between serum uric acid levels and measures of atherosclerosis, such as ABI, carotid IMT used to assess atherosclerosis. This suggests that [higher/lower] uric acid levels may be associated with/not indicative of the presence or severity of atherosclerosis in this population. Our findings are consistent with/partially contradict previous research on the link between uric acid and atherosclerosis, which has shown.¹³

Metabolic Syndrome and Uric Acid

Individuals with metabolic syndrome displayed higher significant difference in serum uric acid levels compared to those without the syndrome. This observation aligns with existing studies suggesting a potential link between metabolic syndrome components and uric acid metabolism.¹⁵

Confounding Variables

Multivariable regression analysis indicated that metabolic syndrome components, e.g., blood pressure, specific lipid levels also influenced the relationship between uric acid and atherosclerosis. This suggests that these factors may play a role in the observed association, highlighting the complex interplay between various components of metabolic syndrome and cardiovascular risk.¹⁴

Reference:

- 1) Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. *BMC Public Health* 2004;4:9. *Am J Cardiol* 2007;100:115-21.
- 2) Lyngdoh T, Marques-Vidal P, Paccad F, Preisig M, Waeber G, Bochud M, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the populationbased Colaus study. *PLoS One* 2011;6:19901.
- 3) Gavin AR, Struthers AD. Hyperuricemia and adverse outcomes in cardiovascular disease: Potential for therapeutic intervention. *Am J Cardiovasc Drugs* 2003;3:309-14.
- 4) Himmelmann A, Kjeldsen SE, Hedner T. Recent hypertension guidelines: JNC-7 and ESH/ESC. *Blood Press* 2003;12:196-7.
- 5) Borges RL, Ribeiro AB, Zanella MT, Batista MC. Uric acid as a factor in the metabolic syndrome. *Curr Hypertens Rep* 2010;12:113-9.
- 6) Cai Z, Xu X, Wu X, Zhou C, Li D. Hyperuricemia and the metabolic syndrome in Hangzhou. *Asia Pac J Clin Nutr* 2009;18:81-7.
- 7) Wilson WF, Agostino R, Parise H, Sullivan L, Meigs J. Metabolic Syndrome as a precursor of Cardiovascular disease and Type 2 diabetes mellitus. *Circulation* 2005;112:3066-72.
- 8) Mangat C, Goel NK, Walia DK, Agarwal N, Sharma MK, Kaur J, et al. Metabolic syndrome: A challenging health issue in highly urbanized union territory of North India. *Diabetol Metab Syndr* 2010;2:19.
- 9) Chen L, Zhu W, Chen Z, Dai H, Ren J, Chen J, et al. Relationship between hyperuricemia and metabolic syndrome. *J Zhejiang Univ Sci B* 2007;8:593-8.

- 10 Chen L, Zhu W. Relationship between hyperuricemia and metabolic syndrome. *J Zhejiang Univ Sci B* 2007;8:593-8.
- 11 Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. *Am J Physiol Renal Physiol* 2006;290:F625-31.
- 12 Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, et al. Uric acid in chronic heart failure: A marker of chronic inflammation. *Eur Heart J* 1998;19:1814-22.
- 13 Olexa P, Olexova M, Gonsorcik J, Tkác I, Kisel'ová J, Olejníková M. Uric acid—a marker for systemic inflammatory response in patients with congestive heart failure. *Wien Klin Wochenschr* 2002;114:211-5.
- 14 Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VS, et al. Uric acid and inflammatory markers. *Eur Heart J* 2006;27:1174-81.
- 15 Ruggiero C, Miller E 3rd, Cherubini A, Maggio M, Najjar SS, Lauretani F, et al. Usefulness of uric acid to predict changes in C reactive protein and Interleukin-6 in 3-year period in Italians aged 21 to 98 years.
- 16 Ebrahimpour P, Fakhrzadeh H, Heshmat R, Bandarian F, Larijani B. Serum uric acid levels and risk of metabolic syndrome in healthy adults. *Endocr Pract* 2008;14:298-304.